We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+10.06%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$278M
AUM Growth
+$69.7M
(+33%)
Cap. Flow
+$59.7M
Cap. Flow
% of AUM
21.48%
Top 10 Holdings %
Top 10 Hldgs %
34.47%
Holding
97
New
38
Increased
13
Reduced
9
Closed
33
Top Buys
| 1 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
+$7.55M |
| 2 |
Community Health Systems
CYH
|
+$7.52M |
| 3 |
CELG
Celgene Corp
CELG
|
+$7.17M |
| 4 |
Merck
MRK
|
+$5.93M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$5.16M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
+$6.13M |
| 2 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$5.28M |
| 3 |
ASRT
Assertio
ASRT
|
+$4.83M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$4.45M |
| 5 |
INSY
Insys Therapeutics, Inc.
INSY
|
+$4.22M |
Sector Composition
| 1 | Healthcare | 71.61% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $22.6M | 8.11% |
+300,000
| New | +$21M |
|
2
Zimmer Biomet
ZBH
$17.6B
| $11.8M | 4.23% |
103,000
+14,214
| +16% | +$1.62M |
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $10.4M | 3.75% |
35,000
+17,500
| +100% | +$4.99M |
|
|
4
Community Health Systems
CYH
$465M
| $7.84M | 2.82% |
+181,500
| New | +$7.52M |
|
|
NUVA
5
DELISTED
NuVasive, Inc.
NUVA
| $7.36M | 2.65% |
160,000
+70,000
| +78% | +$3.25M |
|
6
Puma Biotechnology
PBYI
$434M
| $7.08M | 2.55% |
30,000
| – | – |
|
|
ZSPH
7
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $6.94M | 2.5% |
+165,000
| New | +$7.55M |
|
|
ZLTQ
8
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $6.94M | 2.49% |
225,000
+65,000
| +41% | +$2.08M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $6.92M | 2.49% |
+60,000
| New | +$7.17M |
|
|
PTLA
10
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.83M | 2.46% |
180,000
+30,000
| +20% | +$1.03M |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $6.03M | 2.17% |
+120,000
| New | +$5.16M |
|
|
DYAX
12
DELISTED
DYAX CORPORATION
DYAX
| $5.86M | 2.11% |
350,000
+25,000
| +8% | +$389K |
|
13
Merit Medical Systems
MMSI
$4.41B
| $5.78M | 2.08% |
300,000
+225,000
| +300% | +$4.01M |
|
|
14
Merck
MRK
$315B
| $5.75M | 2.07% |
+104,800
| New | +$5.93M |
|
|
WMGI
15
DELISTED
Wright Medical Group Inc
WMGI
| $5.16M | 1.86% |
200,000
-35,000
| -15% | -$901K |
|
16
Becton Dickinson
BDX
$43.6B
| $5.03M | 1.81% |
+35,875
| New | +$5.02M |
|
|
GNCA
17
DELISTED
Genocea Biosciences, Inc.
GNCA
| $4.98M | 1.79% |
+52,500
| New | +$3.7M |
|
|
NUVA
18
CALL
DELISTED
NuVasive, Inc.
NUVA
| $4.6M | 1.65% |
+100,000
| New | +$4.65M |
|
19
Arcturus Therapeutics
ARCT
$172M
| $4.5M | 1.62% |
+114,286
| New | +$5.03M |
|
|
ADVM
20
DELISTED
Adverum Biotechnologies
ADVM
| $4.46M | 1.6% |
11,000
-1,500
| -12% | -$634K |
|
21
BioMarin Pharmaceuticals
BMRN
$11.5B
| $4.36M | 1.57% |
35,000
-5,000
| -13% | -$530K |
|
|
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $4.29M | 1.54% |
+8,333
| New | +$4.2M |
|
|
CPHD
23
DELISTED
Cepheid Inc
CPHD
| $4.27M | 1.53% |
75,000
-25,000
| -25% | -$1.41M |
|
24
Alnylam Pharmaceuticals
ALNY
$35.7B
| $4.18M | 1.5% |
40,000
-15,000
| -27% | -$1.52M |
|
25
CALL
Agilent Technologies
A
$37.1B
| $4.16M | 1.49% |
+100,000
| New | +$4.05M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2015 Portfolio in Review
As of Q1 2015, Ghost Tree Capital held 97 positions worth $278M, up 33% from $208M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Ghost Tree Capital deployed $59.7M of net new capital in Q1 2015, opening 38 new positions and adding to 13 existing holdings. Its largest new stake was ZS PHARMA INC COMS TK (DE): 165,000 shares worth $6.94M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier, followed by Technology.
On the sell side, the largest reduction was Advaxis Inc, an estimated $3.06M trimmed.
- Ghost Tree Capital's largest Q1 2015 buy was ZS PHARMA INC COMS TK (DE): 165,000 shares worth $6.94M.
- Ghost Tree Capital added most to Allergan plc in Q1 2015, an estimated $4.99M increase.
- Ghost Tree Capital's biggest Q1 2015 reduction was Advaxis Inc, cutting an estimated $3.06M.
- Ghost Tree Capital fully exited Gilead Sciences in Q1 2015, selling an estimated $6.13M.
- Ghost Tree Capital's ten largest holdings make up 34% of its $278M portfolio in Q1 2015.
- Ghost Tree Capital opened 38 new positions and closed 33 in Q1 2015.
- Ghost Tree Capital's portfolio value rose 33% quarter-over-quarter to $278M.
Based on Ghost Tree Capital's 13F filing for Q1 2015, filed 15 May 2015.